Vital Signs - Biomarkers for Improved and Accelerated Sepsis Treatment: Enabling Clinicians to Definitively Diagnose the Disease, Identify the Causative Agent, and Determine the Appropriate Type and Dosage of Antibiotic

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on August 23, 2010, provides a strategic analysis of trends in biomarkers for improved and accelerated sepsis treatment. Additionally, a company spotlight is provided for B•R•A•H•M•S, a global biotechnology company committed to improving healthcare through the discovery and development of novel and innovative biomarkers for the diagnosis, treatment, and therapeutic management of severe, life-threatening diseases. Reimbursement and regulatory news from the FDA is also provided for the week of July 26, 2010.

Table of Contents

Vital Signs - Biomarkers for Improved and Accelerated Sepsis Treatment: Enabling Clinicians to Definitively Diagnose the Disease, Identify the Causative Agent, and Determine the Appropriate Type and Dosage of AntibioticVital Signs: 23 August 2010This week's issue:




Keyword1

Keyword2

Keyword3

Related Research

Release Date : 20-Nov-17

Region : North America

Release Date : 07-Nov-17

Region : North America

Release Date : 06-Nov-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.